Predicting randomized clinical trial results with real-world evidence: A case study in the comparative safety of tofacitinib, adalimumab and etanercept in patients with rheumatoid arthritis
 Share
The version of the browser you are using is no longer supported. Please upgrade to a supported browser.Dismiss

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Toggle screen reader support